At the request of Apotex and Dr Reddys Laboratories, citing scheduling conflicts for their legal counsels, the U.S. District Court for the Southern District of New York has rescheduled the trial date for the Plavix® patent litigation originally set for April 3, 2006.
Today sanofi-aventis announced that Aircoat has withdrawn the revocation action by which it had sought to invalidate the sanofi-aventis patent in the UK claiming clopidogrel bisulfate. Aircoats revocation action was originally announced in January 2005. About sanofi-aventis Sanofi-aventis is the worlds 3rd largest pharmaceutical company, ranking number 1 in Europe. Backed by a world-class R&
On June 15, 2005, the U.S. District Court for the Central District of California granted the Motion for Summary Judgment for inequitable conduct filed by Amphastar Pharmaceuticals, Inc. in the sanofi-aventis Groups suit against Amphastar and Teva Pharmaceuticals USA, Inc. for infringement of US Patent no. 5,389,618 ('618 patent") by their proposed generic versions of Lovenox®. A formal entry o
The Canadian Federal Court of Ottawa has granted sanofi-aventiss application for an order of prohibition against the Minister of Health and Apotex Inc. in relation to Apotexs 2003 application in Canada for a marketing authorization for a generic version of clopidogrel bisulfate tablets. The Canadian Court rejected Apotex's challenge to the Plavix® patent and held that the asserted claims are nov
Sanofi-aventis has learned through the Canadian Ministry of Health website that Novopharm Limited had obtained marketing approval in Canada for a product claiming to be generic enoxaparin. Sanofi-aventis companies Aventis Pharma Inc. and Aventis Pharma S.A. are bringing suit in the Federal Court against Novopharm for patent infringement of Canadian patent 2045433, which covers Lovenox®. Sanofi
Sanofi-aventis has been notified that its patent in the UK issued from its European Patent claiming the active ingredient in its Plavix® product has been challenged by Aircoat, Ltd., a Scottish company, in a Scottish Court. Sanofi-aventis believes Aircoat's arguments to be without merit, and will vigorously defend its patent. Forward-looking statements: This press release contains forward-look
Rhodia announced today that it has commenced legal proceedings in the United States of America and Brazil against sanofi-aventis as former owner or operator of the Silver Bow (United States of America) and Cubatao (Brazil) sites to seek to obtain compensation for environmental liabilities related to these two sites. Aventis and Rhodia signed a final settlement agreement on March 27, 2003 pursua
According to a decision by the European Commission announced today, various producers of MCAA (monochloroacetic acid), an organic chemical used as intermediate in the manufacture of various products, have been fined. This decision was made further to an investigation regarding alleged arrangements affecting competition in certain markets for MCAA. Among those producers, Hoechst, an affiliate of